CREATE
Coordination of resources for conditional expression of mutated mouse alleles
| Coordinatore | EUROPEAN MOLECULAR BIOLOGY LABORATORY
Organization address
address: Meyerhofstrasse 1 contact info |
| Nazionalità Coordinatore | Germany [DE] |
| Totale costo | 1˙287˙738 € |
| EC contributo | 1˙100˙000 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2007-B |
| Funding Scheme | CSA-CA |
| Anno di inizio | 2008 |
| Periodo (anno-mese-giorno) | 2008-11-01 - 2011-10-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
EUROPEAN MOLECULAR BIOLOGY LABORATORY
Organization address
address: Meyerhofstrasse 1 contact info |
DE (HEIDELBERG) | coordinator | 349˙750.00 |
| 2 |
BIOMEDICAL SCIENCES RESEARCH CENTER ALEXANDER FLEMING
Organization address
address: Al. Fleming Street 34 contact info |
EL (VARI-ATHENS) | participant | 294˙250.00 |
| 3 |
CENTRE EUROPEEN DE RECHERCHE EN BIOLOGIE ET MEDECINE
Organization address
address: Rue Laurent Fries 1 contact info |
FR (ILLKIRCH GRAFFENSTADEN) | participant | 155˙274.00 |
| 4 |
Mount Sinai Hospital
Organization address
address: University Avenue 600 contact info |
CA (TORONTO) | participant | 85˙600.00 |
| 5 |
THE JACKSON LABORATORY NON PROFIT CORPORATION
Organization address
address: MAIN STREET 610 contact info |
US (BAR HARBOR) | participant | 85˙600.00 |
| 6 |
HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH
Organization address
address: Ingolstaedter Landstrasse 1 contact info |
DE (MUENCHEN) | participant | 45˙475.00 |
| 7 |
GENOME RESEARCH LIMITED
Organization address
address: THE GIBBS BUILDING, EUSTON ROAD 215 contact info |
UK (LONDON) | participant | 42˙051.00 |
| 8 |
MEDICAL RESEARCH COUNCIL
Organization address
address: NORTH STAR AVENUE POLARIS HOUSE contact info |
UK (SWINDON) | participant | 42˙000.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'This proposal describes CREATE, an internationally based Coordination Action directly addressing a large scale data gathering activity for systematic conditional mouse mutagenesis. Advances in the sophisticated manipulation of the mouse genome has established the mouse as the premier organism for developing models of human disease. Internationally coordinated initiatives have established for the systematic generation of conditional mouse mutants on a large scale employing the Cre-lox binary system. Production of mutant mouse ES cell lines, each of which carries an altered or “floxed” allele of a single gene allows the creation of somatic mutations in defined genes. The full power of conditional mutants can only be exploited with the availability of well characterised mouse lines expressing Cre-recombinase in tissue, organ and cell type-specific patterns. Although several privately curated and locally held databases currently provide a limited catalog of existing Cre driver strains, these are not well integrated, and published data on Cre driver mice do not always capture critical details. CREATE will address these these combined shortcomings - inaccessibility to existing Cre driver strains, their incomplete characterisation, and an inadequate coverage of cell and tissue types in which they are active – which will soon constitute the major bottleneck for the future development of targeted conditional mutant models for the worldwide mouse mutagenesis initiative. Its main deliverables will be a well-annotated and integrated data resource of Cre driver strains, and coordination of the expansion of the resource, both necessary components of the international mouse mutagenesis effort. By enlisting major mouse stakeholders dedicated to collecting, integrating and curating, expanding and disseminating Cre driver mouse databases through a unified web portal, CREATE will provide the necessary structure for worldwide access to these critical resources.'
Introduzione (Teaser)
The mouse is today the main organism used for developing models of human disease. The potential for long-term benefits of this calls for standardised production and use of mouse mutants.